Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Spike Glycoprotein of SARS-CoV-2 (Omicron BA.1) (S protein (Omicron BA.1))
- Target
- S protein (Omicron BA.1)
- Molecular classification
- Viral protein, Glycoprotein, Transmembrane protein
01
Overview
The spike (S) glycoprotein is a large, trimeric, class I fusion protein found on the surface of SARS-CoV-2 virions, specifically the Omicron BA.1 variant. It mediates viral entry into host cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor and facilitating membrane fusion. The S protein is the primary target for neutralizing antibodies and vaccine design. Omicron BA.1 harbors numerous mutations throughout its spike gene compared to earlier variants, altering antigenic sites and potentially enhancing ACE2 affinity or modulating fusogenicity/immune escape.
- Other names
- SARS-CoV-2 Spike protein (Omicron BA.1)Omicron BA.1 Spike proteinS glycoprotein (Omicron BA.1)
02
Mechanism of action
Antibodies bind to the spike protein, preventing ACE2 binding and/or membrane fusion, thus neutralizing the virus. Vaccines induce the production of such antibodies.
03
Biological functions
Receptor binding (ACE2)Membrane fusionViral entryAntigen presentation
04
Disease associations
InfectionCOVID-19 pathogenesis
05
Safety considerations
Antibody-dependent enhancement (ADE)Potential for immune escape due to mutationsVaccine-related adverse events
06
Interacting drugs
Neutralizing antibodies (e.g., monoclonal antibodies)
1 more in the full profile.
07
Biomarkers
Spike protein mutations (e.g., to assess immune escape)Antibody titers against Spike protein (for vaccine efficacy)
Beyond the preview
Go deeper on Spike Glycoprotein of SARS-CoV-2 (Omicron BA.1) (S protein (Omicron BA.1)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spike Glycoprotein of SARS-CoV-2 (Omicron BA.1) (S protein (Omicron BA.1)).